

## **Oral Presentations from Proffered Abstracts**

### **Immunotherapy**

**PR-001** *Ex vivo* co-culture system with patient-derived organoids to assess CXCR4 inhibitor as an immune modulating agent for human pancreas adenocarcinoma. Emily Alouani<sup>1</sup>, Ilenia Pellicciotta<sup>1</sup>, Winston Wong<sup>1</sup>, Alexander S. Thomas<sup>2</sup>, Michael D. Kluger<sup>2</sup>, Anna M. Chiarella<sup>1</sup>, Anil K. Rustgi<sup>1</sup>, Gulam A. Manji<sup>1</sup>. <sup>1</sup>Columbia University Irving Medical Center, New-York, NY, <sup>2</sup>Columbia University, New York, NY.

### **Early Phase Clinical Trials**

**PR-002** A phase II pilot trial of nivolumab (N) + albumin bound paclitaxel (AP) + paricalcitol (P) + cisplatin (C) + gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). Erkut Borazanci<sup>1</sup>, Gayle S. Jameson<sup>1</sup>, Sunil Sharma<sup>1</sup>, Frank Tsai<sup>2</sup>, Ronald L. Korn<sup>3</sup>, Lana Caldwell<sup>2</sup>, Karen Ansaldo<sup>2</sup>, David T. Ting<sup>4</sup>, Denise Roe<sup>5</sup>, Anna Bermudez<sup>2</sup>, Daniel D. Von Hoff<sup>1</sup>. <sup>1</sup>HonorHealth/TGen, Scottsdale, AZ, <sup>2</sup>HonorHealth, Scottsdale, AZ, <sup>3</sup>Imaging Endpoints, Scottsdale, AZ, <sup>4</sup>Massachusetts General, Boston, MA, <sup>5</sup>University of Arizona, Tucson, AZ.

### **Immunotherapy**

**PR-003** High quality neoantigens are immunoedited in long-term pancreatic cancer survivors. Luis A. Rojas<sup>1</sup>, Marta Łuksza<sup>2</sup>, Zachary M. Sethna<sup>1</sup>, Kevin Soares<sup>1</sup>, Joanne Leung<sup>1</sup>, Jayon Lihm<sup>1</sup>, David Hoyos<sup>1</sup>, Anton Dobrin<sup>1</sup>, Rajya Kappagantula<sup>1</sup>, Alvin Makohon-Moore<sup>1</sup>, Amber Johns<sup>3</sup>, Anthony Gill<sup>3</sup>, Masataka Amisaki<sup>1</sup>, Pablo Guasp<sup>1</sup>, Abderezak Zebboudj<sup>1</sup>, Rebecca Yu<sup>1</sup>, Adrienne Kaya Chandra<sup>1</sup>, Zagaa Odgerel<sup>1</sup>, Michel Sadelain<sup>1</sup>, Erin Patterson<sup>1</sup>, Christine Iacobuzio-Donahue<sup>1</sup>, Benjamin D Greenbaum<sup>1</sup>, Vinod P. Balachandran<sup>1</sup>. <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, NY, <sup>2</sup>Icahn School of Medicine at Mount Sinai, New York, NY, <sup>3</sup>Garvan Institute of Medical Research, New South Wales, Australia.

**PR-004** Inhibition of focal adhesion kinase (FAK) improves pancreatic ductal adenocarcinoma's response to immunotherapy by targeting cancer stem cells (CSCs). Yezi Zhu<sup>1</sup>, Lyndsey Sandow<sup>2</sup>, William Matsui<sup>1</sup>. <sup>1</sup>LIVESTRONG Cancer Institute, Dell Medical School, UT Austin, Austin, TX, <sup>2</sup>Oregon Health & Science University, Portland, OR.

### **Big Data**

**PR-005** Chromatin dynamics *in vivo* define coordinate functions of inflammation and mutant Kras in pancreatic tumorigenesis. David Falvo<sup>1</sup>, Jason Pitarresi<sup>2</sup>, Alexa Osterhoudt<sup>1</sup>, Adrien Grimont<sup>1</sup>, Ben Stanger<sup>2</sup>, Steven D. Leach<sup>3</sup>, Anil K. Rustgi<sup>4</sup>, Rohit Chandwani<sup>1</sup>. <sup>1</sup>Weill Cornell Medicine, New York, NY, <sup>2</sup>University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, <sup>4</sup>Columbia University Irving Medical Center, New York, NY.

**PR-006** Integrative genomic characterization of therapeutic targets for pancreatic

**cancer.** Jimmy A. Guo<sup>1</sup>, Daniel Zhao<sup>2</sup>, Scott P. Ginebaugh<sup>3</sup>, Steven Wang<sup>4</sup>, Ananya D. Jambhale<sup>1</sup>, Patrick Z. Yu<sup>1</sup>, Westley W. Wu<sup>1</sup>, Peter Chen<sup>1</sup>, Maryann Zhao<sup>1</sup>, Kristen E. Lowder<sup>3</sup>, Kevin S. Kapner<sup>3</sup>, Hannah I. Hoffman<sup>1</sup>, Stephanie W. Cheng<sup>5</sup>, Daniel Y. Kim<sup>6</sup>, Rebecca Boiarsky<sup>7</sup>, Francois Aguet<sup>1</sup>, Brenton Paoella<sup>1</sup>, John M. Krill-Burger<sup>1</sup>, James M. McFarland<sup>1</sup>, Tobiloba Oni<sup>8</sup>, Tyler Jacks<sup>7</sup>, Aviv Regev<sup>9</sup>, Gad Getz<sup>1</sup>, William L. Hwang<sup>10</sup>, Harshabad Singh<sup>3</sup>, Andrew J. Aguirre<sup>3</sup>. <sup>1</sup>Broad Institute of MIT and Harvard, Cambridge, MA, <sup>2</sup>New York Medical College, Valhalla, NY, <sup>3</sup>Dana Farber Cancer Institute, Boston, MA, <sup>4</sup>Columbia University, New York, NY, <sup>5</sup>Stanford University, Palo Alto, CA, <sup>6</sup>Harvard Medical School, Boston, MA, <sup>7</sup>MIT, Cambridge, MA, <sup>8</sup>Whitehead Institute, Cambridge, MA, <sup>9</sup>Genentech, San Francisco, CA, <sup>10</sup>Massachusetts General Hospital, Boston, MA.

**PR-007 Lung-tropic, liver-averse, primary PDAC tumors are associated with greater peripheral T cell diversity and have a unique, subtype-independent, gene-expression signature that significantly correlates with longer survival.** Jason M. Link, Patrick J. Worth, Dove Keith, Sydney Owen, Alison Grossblatt-Wait, Carl Pelz, Hannah Holly, Motoyuki Tsuda, Kevin MacPherson, Jonathan Brody, Charles Lopez, Brett C. Sheppard, Rosalie C. Sears. <sup>1</sup>Oregon Health & Science University, Portland, OR.

### Signaling

**PR-008 Kdm6 demethylases are critical regulators of pancreatic cancer initiation, progression and subtype specification.** Laura Leonhardt, Lucia Y. Li, David I. Berrios, Sudipta Ashe, Audrey M. Hendley, Grace E. Kim, Matthias Hebrok. University of California San Francisco, San Francisco, CA.

### Metabolism

**PR-009 Targeting the sterol regulatory element-binding protein pathway in pancreatic ductal adenocarcinoma.** Stephanie Myers, Meredith McGuire, Wei Shao, Chine Liu, Theodore Ewachiw, Zeshaan Rasheed, William Matsui, Toni Sepalla, Richard Burkhart, Peter Espenshade. Johns Hopkins University, School of Medicine, Baltimore, MD.

### Signaling

**PR-010 Collateral amplification of the *KRAS* linked gene *PTHLH* governs pancreatic cancer growth and metastasis and reveals a new therapeutic vulnerability.** Jason R. Pitarresi<sup>1</sup>, Robert J Norgard<sup>1</sup>, Anna M. Chiarella<sup>2</sup>, Kensuke Suzuki<sup>2</sup>, Richard Kremer<sup>3</sup>, Ben Z. Stanger<sup>1</sup>, Anil K. Rustgi<sup>2</sup>. <sup>1</sup>University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Columbia University, New York City, NY, <sup>3</sup>McGill University, Montreal, QC, Canada.

**PR-011 Loss of compensatory feedback mechanism involving splicing factor SRSF1 accelerates *Kras*<sup>G12D</sup>-mediated pancreatic cancer initiation.** Ledong Wan, Kuan-Ting Lin, Mohammad A. Rahman, Zhikai Wang, Youngkyu Park, David A. Tuveson, Adrian R. Krainer. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

## Tumor Microenvironment

**PR-013 The splanchnic mesenchyme during fetal development is the major source of pancreatic cancer associated fibroblasts.** Lu Han<sup>1</sup>, Yongxia Wu<sup>1</sup>, Melodie Parrish<sup>1</sup>, Khushbu Patel<sup>1</sup>, Xuezhong Yu<sup>1</sup>, Michael Ostrowski<sup>1</sup>, Gustavo Leone<sup>2</sup>. <sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>Medical College of Wisconsin, Milwaukee.

**PR-014 Hedgehog represses angiogenesis in PDAC through a paracrine cascade mediated by Wif1.** Marie C. Hasselluhn<sup>1</sup>, Amanda R. Decker<sup>1</sup>, Alvaro Curiel Garcia<sup>1</sup>, Carlo Maurer<sup>2</sup>, Dafydd Thomas<sup>3</sup>, Kenneth P. Olive<sup>1</sup>. <sup>1</sup>Columbia University Irving Medical Center, New York, NY, <sup>2</sup>Technische Universität München, Munich, Germany, <sup>3</sup>PMV Pharmaceuticals, Inc., Cranbury, NJ.

**PR-015 Cancer-associated fibroblasts sustain critical dependency of pancreatic cancer cells on exogenous lipids.** Charline Ogier<sup>1</sup>, Alena Klochkova<sup>2</sup>, Linara Gabitova<sup>1</sup>, Battuya Bayarmagnai<sup>3</sup>, Diana Restifo<sup>1</sup>, Aizhan Surumbayeva<sup>1</sup>, Janusz Franco-Barraza<sup>1</sup>, Ralph Francescone<sup>1</sup>, Debora B. Barbosa Vendramini-Costa<sup>1</sup>, Jaye Gardiner<sup>1</sup>, Emmanuelle Nicolas<sup>4</sup>, Elizabeth A. Handorf<sup>5</sup>, KATHY Q. Cai<sup>6</sup>, Edna Cukierman<sup>1</sup>, Igor Astsaturov<sup>1</sup>. <sup>1</sup>The Marvin & Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Philadelphia, PA, <sup>2</sup>Temple University Lewis Katz School of Medicine, Philadelphia, PA, <sup>3</sup>Department of Bioengineering, Temple University, Philadelphia, PA, <sup>4</sup>Genomic Facility, Fox Chase Cancer Center, Philadelphia, PA, <sup>5</sup>Biostatistic Facility, Fox Chase Cancer Center, Philadelphia, PA, <sup>6</sup>Histopathology Facility, Fox Chase Cancer Center, Philadelphia, PA.

**PR-016 Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming.** Ashley Velez-Delgado, Katelyn L. Donahue, Kristee L. Brown, Wenting Du, Valerie Irizarry-Negron, Rosa E. Menjivar, Emily L. Lasse-Opsahl, Nina G. Steele, Stephanie The, Jenny Lazarus, Veerin R. Sirihorachai, Filip Bednar, Timothy L. Frankel, Yaqing Zhang, Marina Pasca di Magliano. University of Michigan, Ann Arbor, MI.